Thus, bi-specific T cell engaging antibodies were envisioned as a means of redirecting more potent T cell responses against tumours, leading to the development of blinatumomab, a CD19-CD3 BiTE used to treat acute lymphoblastic leukemia, as well as other BiTE therapeutics at various stages of pre-clinical and clinical development [6]. The gene discussed is CD19; the disease is neoplasm.